Significant media outlets are way off base in making a story of what seems an insignificant investment that President Trump holds in a company that makes the anti-malarial drug hydroxychloroquine. Trump has been promoting the drug as a treatment for COVID-19, it is true, but this attack is appears to be a cheap shot, bordering on a smear. Even a hardened Never Trumper can see that.

The report first appeared in an aside buried in a larger story in the New York Times. The Times noted that Trump has three family trusts that each have an investment in a mutual fund that, in turn, has large holdings in a drug company that makes Plaquenil, the brand-name version of hydroxychloroquine.